MTR (FRA:MRI) YoY EBITDA Growth: -64.25% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MRI MTR Corp Ltd FRA:MRI
77 GF Score
Price €3.54
GF Value €2.78
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is MTR YoY EBITDA Growth?

MTR FRA:MRI -0.56% 77 YoY EBITDA Growth is -64.25% as of Jun. 2026. GuruFocus rates FRA:MRI with a GF Score™ of 77/100 and a GF Value™ of €2.78 (Modestly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MTR's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -64.25%.

MTR's EBITDA per Share for the six months ended in Jun. 2026 was €0.07.

MTR YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MTR's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MTR YoY EBITDA Growth Chart

MTR Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 777.78 5.74 -15.12 97.26 -13.43

MTR Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.75 148.60 19.88 -31.58 -64.25
FRA:MRI
77GF Score
MTR Corp Ltd FRA:MRI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MTR YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MTR's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.374-0.432)/ | 0.432 |
=-13.43 %

MTR's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.069-0.193)/ | 0.193 |
=-64.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -64.25% mean?
MTR (FRA:MRI) has a YoY EBITDA Growth of -64.25% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MTR and its competitors.
Is MTR's YoY EBITDA Growth too high?
MTR's current YoY EBITDA Growth is -64.25%. Overall, MTR has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MTR's YoY EBITDA Growth compare to UNP and CSX?
MTR's YoY EBITDA Growth of -64.25% can be compared against companies in the Transportation industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Transportation company?
A good YoY EBITDA Growth depends on the Transportation industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MTR and its competitors. MTR's current YoY EBITDA Growth is -64.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MTR stock overvalued right now?
Based on GuruFocus' analysis, MTR (FRA:MRI) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.78, compared to a current price of €3.54 — trading 27.3% above its estimated fair value. The current YoY EBITDA Growth is -64.25%. MTR's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MTR (FRA:MRI), the current YoY EBITDA Growth is -64.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MTR (FRA:MRI) Overvalued in 2026?

Based on GuruFocus' analysis, MTR stock appears to be overvalued. The current stock price of €3.54 is trading 27.3% above its estimated GF Value™ of €2.78. GuruFocus considers MTR to be Modestly Overvalued.

Key valuation signals for FRA:MRI:

  • YoY EBITDA Growth: -64.25%
  • GF Value™: €2.78 vs. price of €3.54 (27.3% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the FRA:MRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MTR Business Description

Address Kowloon Bay, GPO Box 9916, MTR Headquarters Building, Telford Plaza, Kowloon, Hong Kong, HKG
MTR constructs and operates Hong Kong's rail network, giving it a monopoly position. In addition to rail operation, the company makes recurring income from commercial business in the stations. This includes rental of retail kiosks and advertisement in the stations and investment properties in shopping malls above stations. Residential real estate development forms part of MTR's return for the rail operation. In a normalized environment, average operating profit is approximately 20% in rail operation, 60% in station commercial and property leasing business, and 20% in property development. The Hong Kong government owns 75% of MTR.
77GF Score

Get the complete analysis for FRA:MRI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.54
Price
€2.78
GF Value